| Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants | |
| Chen, Jia-Feng; Xiao, Ling-Fei; Zhang, Ran; Zeng, Zi-Hang; Li, Yi-Xuan; Meng, Xiang-Yu | |
| 刊名 | ACTA HAEMATOLOGICA
 |
| 2017 | |
| 卷号 | 137期号:4 |
| ISSN号 | 0001-5792 |
| DOI | 10.1159/000471839 |
| URL标识 | 查看原文 |
| 收录类别 | SCIE |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4086204 |
| 专题 | 武汉大学 |
| 推荐引用方式 GB/T 7714 | Chen, Jia-Feng,Xiao, Ling-Fei,Zhang, Ran,et al. Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants[J]. ACTA HAEMATOLOGICA,2017,137(4). |
| APA | Chen, Jia-Feng,Xiao, Ling-Fei,Zhang, Ran,Zeng, Zi-Hang,Li, Yi-Xuan,&Meng, Xiang-Yu.(2017).Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.ACTA HAEMATOLOGICA,137(4). |
| MLA | Chen, Jia-Feng,et al."Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants".ACTA HAEMATOLOGICA 137.4(2017). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论